 WHIPPANY, N.J. SOUTH SAN FRANCISCO, Calif.--BUSINESS WIRE--Bayer and Veracyte Nasdaq:VCYT today announced a new collaboration to advance the Precision Oncology Patient Identification Program in thyroid cancer. Through the program, Bayer will offer testing with Veracytes Afirma Xpression Atlas XA to identify underlying genomic drivers, including NTRK gene fusions, within patients tumors. The program will focus on patients with advanced or metastatic thyroid cancer that is radioactive i 